Alpha Therapeutics holding four lots of AlphaNine SD coagulation Factor IX for HAV safety review.
Executive Summary
ALPHA THERAPEUTICS CONDUCTING HEPATITIS A REVIEW OF ALPHANINE SD coagulation Factor IX (human) lots CA5410A, CA5412A, CA5413A and CA5421A and advises distributors in a Jan. 12 letter that "these lots are on hold pending the confirmation of their safety." FDA says the four lots of Factor IX were produced using plasma pools common to Alphanate Factor VIII lot AP5014A, which was voluntarily withdrawn from the market Dec. 8 due to three suspected hepatitis A virus transmissions. Two of the transmissions were definitively linked to the plasma product by polymerase chain reaction testing completed by the Centers for Disease Control & Prevention Jan. 12.
You may also be interested in...
Part D Discount Liability Coming Into Focus: CMS Releases Drug Cost Data
Newly released Medicare Part D data sheds light on the sales hit that branded pharmaceutical manufacturers will face when the coverage gap discount program gets under way in 2011
FDA Skin Infections Guidance Spurs Debate On Endpoint Relevance
FDA appears headed for a showdown with clinicians and the pharmaceutical industry over the proposed new clinical trial endpoints for acute bacterial skin and skin structure infections, the guidance's approach for justifying a non-inferiority margin and proposed changes in the types of patients that should be enrolled in trials
Shire Hopes To Sow Future Deals With $50M Venture Fund
Specialty drug maker Shire has quietly begun scouting deals with a brand-new $50 million venture fund, the latest of several in-house investment arms to launch with their parent company's pipelines, not profits, as the measure of their worth